Sharifi N - Search Results

1

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. Yang M, et al. Among authors: sharifi n. J Clin Oncol. 2011 Jun 20;29(18):2565-73. doi: 10.1200/JCO.2010.31.2405. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606417 Free PMC article.

2

Androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL. Sharifi N, et al. JAMA. 2005 Jul 13;294(2):238-44. doi: 10.1001/jama.294.2.238. JAMA. 2005. PMID: 16014598 Review.

3

A retrospective study of the time to clinical endpoints for advanced prostate cancer.

Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL. Sharifi N, et al. BJU Int. 2005 Nov;96(7):985-9. doi: 10.1111/j.1464-410X.2005.05798.x. BJU Int. 2005. PMID: 16225513

4

Androgen receptor modulation: lessons learned from beyond the prostate.

Sharifi N, Figg WD. Sharifi N, et al. Cancer Biol Ther. 2007 Sep;6(9):1358-9. doi: 10.4161/cbt.6.9.4825. Epub 2007 Aug 3. Cancer Biol Ther. 2007. PMID: 17881894 Free article. Review.

5

Secondary hormonal therapy for prostate cancer: what lies on the horizon?

Sharifi N, Dahut WL, Figg WD. Sharifi N, et al. BJU Int. 2008 Feb;101(3):271-4. doi: 10.1111/j.1464-410X.2007.07236.x. Epub 2007 Oct 8. BJU Int. 2008. PMID: 17922868 Review.

6

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. Hamada A, et al. Among authors: sharifi n. Clin Cancer Res. 2008 Jun 1;14(11):3312-8. doi: 10.1158/1078-0432.CCR-07-4118. Clin Cancer Res. 2008. PMID: 18519758 Free PMC article.

7

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.

Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD. Sharifi N, et al. BJU Int. 2008 Aug 5;102(5):617-21. doi: 10.1111/j.1464-410X.2008.07629.x. Epub 2008 Jun 4. BJU Int. 2008. PMID: 18537956 Free PMC article.

8

The genetics of castration-resistant prostate cancer: what can the germline tell us?

Sharifi N, Dahut WL, Figg WD. Sharifi N, et al. Clin Cancer Res. 2008 Aug 1;14(15):4691-3. doi: 10.1158/1078-0432.CCR-08-0453. Clin Cancer Res. 2008. PMID: 18676736 Free PMC article. Review.

9

More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

Ajiboye S, Sissung TM, Sharifi N, Figg WD. Ajiboye S, et al. Among authors: sharifi n. BJU Int. 2010 Apr;105(7):913-6. doi: 10.1111/j.1464-410X.2009.08999.x. Epub 2010 Jan 8. BJU Int. 2010. PMID: 20067462 Free PMC article. Review.

10

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

371 results

Search Page

Filters